UK markets close in 8 hours 25 minutes

Ocugen, Inc. (OCGN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.8400+0.1600 (+5.97%)
At close: 04:00PM EDT
2.8100 -0.03 (-1.06%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.6800
Open2.7500
Bid0.0000 x 1100
Ask0.0000 x 800
Day's range2.6970 - 2.8750
52-week range1.6700 - 17.6500
Volume5,784,196
Avg. volume6,181,170
Market cap615.047M
Beta (5Y monthly)4.21
PE ratio (TTM)N/A
EPS (TTM)-0.3470
Earnings date07 Nov 2022 - 11 Nov 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est7.60
  • Motley Fool

    Here's How This Beaten-Down Stock Could 10X by 2024

    On that note, Ocugen (NASDAQ: OCGN) stock is down by more than 65% this year as the small biotech has struggled to commercialize a coronavirus vaccine. To remedy that issue, it's licensing a coronavirus vaccine called Covaxin from Bharat Biotech, an Indian pharmaceutical business. While it's already approved in India, the chances of Ocugen successfully commercializing Covaxin in the U.S. remain a question mark.

  • Motley Fool

    1 Robinhood Stock to Avoid Right Now

    Commission-free trading platform Robinhood Markets grew in prominence helping newer investors participate in what remains one of the best ways to accumulate wealth over time. One example is Ocugen (NASDAQ: OCGN). Can Ocugen succeed in the COVID-19 vaccine market?

  • Motley Fool

    Ocugen, Inc. (OCGN) Q2 2022 Earnings Call Transcript

    Joining me today are Ocugen's chairman and CEO and co-founder, Dr. Shankar Musunuri, who will provide a business update; and our chief accounting officer and senior vice president of finance, Jessica Crespo, who will provide more on our financial results. Earlier this morning, we issued a press release detailing business activity for Q2 2022.